Gene therapy pipeline
Explore GenSight Biologics' clinical development of gene therapy product candidates, including clinical trials for GS010 in LHON and GS030 in retinitis pigmentosa.
gensight-biologics.comCrawled Nov 14, 2026
Explore GenSight Biologics' clinical development of gene therapy product candidates, including clinical trials for GS010 in LHON and GS030 in retinitis pigmentosa.
Leber Hereditary Optic Neuropathy (LHON) is a rare mitochondrial disease causing sudden, severe, and irreversible vision loss.
GenSight Biologics’ Mitochondrial Targeting Sequence (MTS) platform enables gene therapy to target mitochondrial diseases and restore vision.
GenSight Biologics’ Mitochondrial Targeting Sequence (MTS) platform extends gene therapy to mitochondrial dysfunctions.
GenSight’s optogenetics platform combines gene therapy with a light-stimulating medical device to restore vision.
Retinitis Pigmentosa (RP) is an inherited retinal disease causing degeneration of photoreceptor cells and progressive vision loss.
The OIS Retina Innovation Summit, preceding ASRS, takes place on October 7 at the Grand Hyatt San Antonio River Walk. GenSight Biologics sponsors the event as a Bronze sponsor, with Dr. Magali Taiel presenting the company and its latest updates.
GenSight Biologics publishes financial press releases on company updates, clinical programs, and investor events.
Read GenSight Biologics' financial press releases covering news about company developments, clinical programs and investor events.
GenSight Biologics secures a €35 million credit facility to support LUMEVOQ development and marketing in Europe.
December 2, 2021, at 8:00 am EST / 2:00 pm CET Connection details for live call and translation provided
GenSight Biologics provides shareholder letters detailing progress and company operations.
GenSight Biologics introduces its international board of directors, which provides strategic guidance.
GenSight Biologics introduces its international board of directors, guiding the company’s gene therapy strategy.
GenSight Biologics outlines its governance structure.
GenSight Biologics presents its executive team, overseeing its gene therapy programs for inherited eye diseases.
GenSight Biologics presents its executive team, which leads the company’s strategy and gene therapy programs for inherited eye diseases.
GenSight Biologics describes its governance structure.
GenSight Biologics shares its history and current gene therapy programs focused on vision.
Discover GenSight Biologics' ambitions and history,from its founding to its present gene therapy programs focused on vision restoration.
GenSight Biologics is a biotech company pioneering gene therapy for inherited retinal diseases to restore vision.
GenSight Biologics provides its cookie policy in French.
GenSight Biologics provides its privacy policy in French.
GenSight Biologics provides its legal notice.
GenSight Biologics displays its legal notice.
GenSight Biologics presents its terms of use.
GenSight Biologics outlines its terms of use.